Meeting
2020 ASCO Virtual Scientific Program
Clinical experience of ONC201 in patients with recurrent H3 K27M-mutant spinal cord glioma.
Authors
Sylvia Christine Kurz
NYU Langone Health, New York, NY
Sylvia Christine Kurz , Rohinton Tarapore , Yazmin Odia , Nicholas A. Butowski , Carl Johannes Koschmann , Dolly Aguilera , Tobey J. MacDonald , Guangrong Lu , Joshua E. Allen , Wolfgang Oster , Minesh P. Mehta , Andrew S. Chi , Patrick Y. Wen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT02525692; NCT03295396; NCT03416530
Citation
J Clin Oncol 38: 2020 (suppl; abstr 2563)
DOI
10.1200/JCO.2020.38.15_suppl.2563
Abstract #
2563
Poster Bd #
54
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Malignant glioma subset from Actuate 1801: A phase 1/2 study of 9-ING-41, a glycogen synthase kinase 3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory hematologic malignancies or solid tumors.
First Author: Yazmin Odia
Poster
2020 ASCO Virtual Scientific Program
Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma.
First Author: Isabel Arrillaga-Romany
First Author: Andrew S. Chi
Poster
2013 ASCO Annual Meeting
Post-bevacizumab treatment and clinical outcomes in recurrent malignant glioma.
First Author: Yongjun Cha